Integra Lifesciences Holdings (IART) Gross Profit (2009 - 2026)

Integra Lifesciences Holdings (IART) has 18 years of Gross Profit data on file, last reported at $217.0 million in Q1 2026.

• For the quarter ending Q1 2026, Gross Profit rose 11.6% year-over-year to $217.0 million; the trailing twelve-month figure through Mar 2026 stood at $854.2 million (down 1.78% YoY), and the FY2025 full-year result was $831.6 million, down 5.72% from the prior year.
• Gross Profit fell to $217.0 million in Q1 2026, from $220.9 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $250.1 million in Q4 2022 to a low of $194.4 million in Q1 2025.
• A 5-year average of $222.7 million and a median of $220.9 million in 2025 frame the typical range for Gross Profit.
• Across the five-year window, Gross Profit slipped 16.99% in 2023 and advanced 11.6% in 2026, its largest moves.
• Tracing IART's Gross Profit over 5 years: stood at $250.1 million in 2022, then slipped by 9.43% to $226.5 million in 2023, then increased by 9.97% to $249.1 million in 2024, then fell by 11.32% to $220.9 million in 2025, then fell by 1.76% to $217.0 million in 2026.
• Business Quant data shows IART's Gross Profit at $217.0 million in Q1 2026, $220.9 million in Q4 2025, and $207.0 million in Q3 2025.